$2.25B Into Biopharma as Hospitals Hunt for Margin

Good morning, ! Hospital leaders are betting on labor productivity to repair margins, McKesson is putting $2.25B behind its biopharma expansion, and APAC hospitals are embracing AI—though mostly outside the clinic. Plus, rising healthcare costs are pulling CFOs deeper into benefits decisions.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

Labor Is the Margin Lever

Hospital leaders see workforce productivity as the clearest route to stronger margins. In our survey, 48% selected labor productivity as the lever with the greatest potential to improve hospital margins over the next three years, well ahead of revenue cycle optimization at 31% and service-line and patient mix at 21%.

The result points to where operators see the largest controllable cost base. Rather than relying primarily on reimbursement improvement or portfolio shifts, respondents are prioritizing getting more capacity from existing clinical and administrative resources.

For investors and healthcare executives, that changes the technology and services opportunity. Solutions tied to workflow automation, staffing efficiency, scheduling, documentation, and other measurable productivity gains should face a more receptive buyer, but only if savings translate into the P&L.

Bottom line: The next hospital margin cycle may be won less through revenue growth than through operating leverage. Vendors that can quantify labor hours saved, capacity created, or cost removed will have the strongest position. (More)

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

HEADLINE OF THE WEEK

Healthcare Costs Move Into the C-Suite

Employer healthcare is becoming a balance-sheet problem. Firms expect median healthcare costs to rise 9.2% in 2027, or 8% after plan changes. If current trends hold, cumulative costs will have increased 76% over the past decade.

That pressure is changing who makes benefits decisions. 88% of employers say senior leadership is paying closer attention to healthcare, while 59% report greater involvement from CFOs and finance teams. Cost containment is following. GLP-1 obesity coverage fell from 72% in 2025 to 60% in 2026, while 47% of employers are considering an alternative PBM for 2028 or 2029.

The implication extends beyond benefits departments. Vendors, PBMs, health plans, and digital health companies are increasingly selling into a procurement process shaped by finance-grade expectations around measurable savings and utilization. With 58% of employers prepared to replace underperforming vendors or eliminate low-utilization programs, weak ROI is becoming harder to defend.

Bottom line: Healthcare benefits are shifting from an HR expense to an enterprise cost center. That raises the bar for vendors. Clinical value still matters, but demonstrable economic value increasingly determines who keeps the contract. (More)

DEAL OF THE WEEK

McKesson Goes Deeper Into Biopharma

McKesson is putting $2.25B behind its push beyond pharmaceutical distribution.

The healthcare giant agreed to acquire Precision Medicine Group, adding clinical research, biomarker, market access and commercialization capabilities to its Oncology & Multispecialty segment.

The deal extends a broader strategy of moving closer to both biopharma and specialty-care providers. McKesson has already expanded its oncology footprint through Florida Cancer Specialists and into ophthalmology through PRISM Vision.

The bottom line: Distribution built McKesson’s scale. Now, clinical research and commercialization are helping it capture more of the drug lifecycle—and more of the economics around it.

Read more

DEAL TRACKER

>$1.5B | Sentivera → Haisco Immunology Asset
Sentivera secured ex-Greater China rights to Haisco’s type 2 inflammation asset for $75.89M upfront plus up to $1.46B in milestones, highlighting momentum in China-origin biotech licensing. Read more

Undisclosed | Linden Capital Partners → ArtesRx
Linden acquired ArtesRx from Flexpoint Ford after the behavioral health pharmacy platform expanded from 3 to 16 pharmacies, underscoring continued PE appetite for specialty pharmacy. Read more

Undisclosed | BVP Forge → Nevvon
BVP Forge invested in Nevvon, a training and compliance platform serving 650,000+ home-care caregivers, backing further growth in technology-enabled workforce infrastructure. Read more

Undisclosed | 360training → eMedCert
360training acquired select eMedCert assets, adding a platform that has delivered 150,000+ life-support certifications and expanding its healthcare training and recertification offering. Read more

REGIONAL FOCUS

APAC’s AI Boom Is Still Mostly Back-Office

AI adoption across Asia-Pacific healthcare is accelerating—but hospitals are still using it more as an efficiency tool than a clinical one.

According to a recent HIMSS report covered by Healthcare Asia, 51% of APAC healthcare organizations now use AI daily or nearly daily, while GenAI adoption reaches 81%.

Yet deployment remains deskbound. Workflow optimization (74%), medical documentation (65%) and administrative efficiency (64%) lead current use cases. By comparison, only 45% report improved diagnostic accuracy and 33% better patient engagement.

The bottom line: APAC’s next AI opportunity is moving from adoption to clinical integration. For investors, that shifts the opportunity toward the infrastructure, governance and workflow tools required to take AI from the back office to the bedside.

Read more

INTERESTING ARTICLES